CD274 and neoplasm: When exosome surface PD-L1 attaches to the anti-PD-L1 antibody, leaving the tumour PD-L1 exposed, or when exosome surface PD-L1 binds to PD-1 on effector T cells during monoclonal antibody therapy, tumour cells can specifically bypass immunosuppression [115].